Table 3.
Incidence of AEs
| Incidence of AEs | Fingolimod Alone, n = 26 | Carbamazepine Alone (Titration and Top Dose), n = 23 | Fingolimod + Carbamazepine Combination, n = 20 |
|---|---|---|---|
| Subjects with AE(s) | 6 (23.1) | 16 (69.6) | 6 (30.0) |
| Nervous system disorders | 1 (3.8) | 14 (60.9) | 2 (10.0) |
| Gastrointestinal disorders | 3 (11.5) | 6 (26.1) | 2 (10.0) |
| General disorders and administration‐site condition | 0 (0.0) | 3 (13.0) | 3 (15.0) |
| Skin and subcutaneous tissue disorders | 0 (0.0) | 5 (21.7) | 0 (0.0) |
| Investigations | 1 (3.8) | 3 (13.0) | 0 (0.0) |
| Metabolism and nutrition disorders | 0 (0.0) | 4 (17.4) | 0 (0.0) |
| Musculoskeletal and connective tissue disorders | 0 (0.0) | 4 (17.4) | 0 (0.0) |
| Eye disorders | 0 (0.0) | 1 (4.3) | 1 (5.0) |
| Infections and infestations | 1 (3.8) | 0 (0.0) | 1 (5.0) |
| Injury, poisoning, and procedural complications | 0 (0.0) | 1 (4.3) | 0 (0.0) |
| Psychiatric disorders | 0 (0.0) | 1 (4.3) | 0 (0.0) |
| Renal and urinary disorders | 0 (0.0) | 1 (4.3) | 0 (0.0) |
AE, adverse event.